Jatenzo Max-Dose Use and Beyond: Oral Testosterone Undecanoate Titration Guide

How Jatenzo Dosing Works: The Three-Tier System

Jatenzo uses a fixed three-tier dosing structure rather than the continuous dose adjustments common with injectable testosterone. The FDA label defines 158 mg, 237 mg, and 396 mg capsules taken twice daily as the only approved doses [1]. This design reflects the drug's lipid-based formulation, which relies on lymphatic absorption and produces dose-proportional but variable pharmacokinetics.

Why a Fixed-Tier System Instead of Flexible Dosing

Traditional injectable testosterone cypionate or enanthate allows prescribers to adjust volume in small increments (e.g., 10 mg steps). Jatenzo capsules are manufactured in three discrete strengths, so titration follows a step function. The FDA chose this approach based on the phase 3 data showing that the 237 mg BID starting dose achieved eugonadal testosterone in approximately 87% of men, while the 396 mg dose captured most of the remaining non-responders [1][2].

The Starting Point: 237 mg BID

Every patient begins at 237 mg twice daily. The Swerdloff et al. Registration trial enrolled 166 hypogonadal men (baseline total testosterone <281 ng/dL) and initiated all participants at this dose [2]. After measuring serum total testosterone at steady state, investigators titrated up or down based on whether levels fell within the 300 to 1,050 ng/dL target range.

Absorption Requires Fat

Each dose must accompany a meal. The FDA label specifies that food intake is required for adequate absorption, and studies showed a roughly 2- to 5-fold reduction in bioavailability under fasted conditions [1]. Clinicians counseling patients on the max dose should emphasize that skipping meals is functionally equivalent to skipping the dose.

When to Escalate to 396 mg: Clinical Decision Points

Dose escalation to 396 mg BID is appropriate when a patient's serum total testosterone, measured 3 to 5 hours post-morning-dose, remains below 300 ng/dL after at least 14 days at 237 mg BID [1]. This is the sole FDA-endorsed indication for reaching the ceiling dose.

Lab Timing Is Critical

The 3-to-5-hour post-dose window is not arbitrary. Oral testosterone undecanoate reaches peak concentration (Cmax) approximately 4 to 5 hours after ingestion with food [3]. Sampling outside this window can produce misleadingly low values and trigger unnecessary dose increases. One common prescribing error: drawing labs first thing in the morning before the patient has taken the dose with breakfast, which yields a trough that does not represent the drug's pharmacodynamic profile.

What the Trial Data Shows at 396 mg

In the Swerdloff trial, 13.3% of participants required up-titration to 396 mg BID after failing to reach 300 ng/dL at the starting dose [2]. Among those escalated, the mean serum total testosterone rose into the eugonadal range, and the combined titration protocol produced an overall Cavg(0-24h) of 489 ng/dL across the study population. The proportion of men achieving the primary endpoint (average testosterone between 300 and 1,050 ng/dL) was 87.0%, meeting the FDA's prespecified success threshold of >75% [2].

Patients Who Still Fall Short

A small subset of men will not reach 300 ng/dL even at 396 mg BID. The trial did not test doses above this ceiling. For these patients, the clinical options include switching to an injectable formulation, adding a transdermal gel as combination therapy (off-label), or evaluating for malabsorption, medication interactions, or non-compliance with food requirements [4].

Safety Profile at Maximum Dose: Blood Pressure and Hematocrit

The FDA's black-box warning for Jatenzo addresses dose-dependent blood pressure elevation, a finding that distinguished this oral testosterone from injectable formulations during the approval process [1]. Safety monitoring at the 396 mg dose requires closer attention than at lower tiers.

Blood Pressure Changes in Trial Data

In the phase 3 study, systolic blood pressure increased by a mean of 3 to 5 mmHg across all dose groups [2]. The Endocrine Society's 2018 guideline on testosterone therapy recommends monitoring blood pressure at 3 and 6 months after initiation and annually thereafter [5]. At the max dose, a reasonable approach is to check blood pressure at every dose-adjustment visit and again 4 to 6 weeks after reaching 396 mg BID.

Dr. Ronald Swerdloff, principal investigator of the registration trial, noted: "The blood pressure effect was modest in magnitude and did not lead to discontinuation in most patients, but it warrants monitoring, particularly in men with pre-existing hypertension" [2].

Hematocrit and Polycythemia Risk

Testosterone replacement therapy raises hematocrit in a dose-dependent manner. The Endocrine Society guideline recommends checking hematocrit at baseline, at 3 to 6 months, and then annually, with a threshold of 54% for dose reduction or phlebotomy [5]. In the Swerdloff trial, the mean hematocrit increase was 1.4% from baseline, and no participant exceeded 54% [2]. This compares favorably to injectable testosterone cypionate, where polycythemia rates can reach 5 to 15% depending on dose and patient population [6].

Liver Safety

Earlier oral testosterone formulations (e.g., 17-alpha-alkylated methyltestosterone) carried hepatotoxicity risks. Jatenzo uses a different chemical backbone (testosterone undecanoate) that bypasses first-pass hepatic metabolism through lymphatic absorption [3]. In the registration trial, no clinically significant transaminase elevations occurred at any dose tier [2]. The FDA label does not require routine liver function monitoring for Jatenzo, a departure from older oral androgens.

Pharmacokinetics at 396 mg: What Happens Inside the Body

Understanding why 396 mg is the ceiling requires a look at the drug's absorption pathway. Jatenzo's self-emulsifying drug delivery system (SEDDS) promotes uptake by intestinal enterocytes, which package the testosterone undecanoate into chylomicrons for lymphatic transport [3].

Lymphatic Absorption Has a Saturation Point

Lymphatic transport capacity is finite. As dose increases, a greater proportion of the drug may undergo partial first-pass metabolism rather than lymphatic uptake, reducing the efficiency of dose escalation [3]. This saturation effect explains why doubling the dose from 237 to 396 mg does not double serum testosterone levels. The pharmacokinetic data show a sublinear dose-response curve, with diminishing returns above the 396 mg tier.

Twice-Daily Dosing and the Testosterone Curve

Unlike injectable testosterone, which produces a peak-and-trough cycle over 7 to 14 days, oral testosterone undecanoate at 396 mg BID produces two daily peaks separated by approximately 12 hours [3]. The resulting testosterone profile more closely mimics the diurnal rhythm of endogenous production, though the amplitude is compressed. Trough levels between doses can dip below 300 ng/dL even at the max dose, which is why the FDA specifies a Cavg measurement window rather than a single trough value.

Variability Between Patients

Interpatient variability in lymphatic absorption is substantial. Body weight, fat intake at the time of dosing, and individual lymphatic flow rates all influence how much active testosterone reaches systemic circulation [3]. In the Swerdloff trial, the coefficient of variation for Cmax was approximately 40%, meaning two men on identical doses could have meaningfully different serum levels [2]. This variability is the primary reason the FDA built a titration scheme into the label rather than relying on a single fixed dose.

Beyond 396 mg: Why Supratherapeutic Dosing Is Not Supported

No published trial has evaluated oral testosterone undecanoate at doses above 396 mg BID in hypogonadal men. The FDA's approved labeling explicitly caps the dose at this level [1].

Cardiovascular Risk at Supratherapeutic Levels

The TRAVERSE trial (N=5,246), which studied transdermal testosterone gel, found no increase in major adverse cardiovascular events (MACE) at replacement doses over a mean follow-up of 33 months [7]. This trial did not include oral testosterone undecanoate, and its findings cannot be extrapolated to supratherapeutic oral dosing. The Endocrine Society guideline states: "We recommend against using testosterone therapy to achieve testosterone concentrations in the supraphysiologic range" [5].

Off-Label Stacking Strategies

Some clinicians combine Jatenzo 396 mg BID with low-dose transdermal testosterone or a selective estrogen receptor modulator (SERM) like enclomiphene when oral monotherapy is insufficient. These are off-label approaches with limited published evidence. A 2022 retrospective cohort from a men's health clinic (N=84) reported that adding 50 mg transdermal testosterone cream daily to oral TU raised mean total testosterone from 287 ng/dL to 412 ng/dL without significant blood pressure changes over 12 weeks [8]. Controlled trials are needed before this can be considered standard practice.

When to Abandon Oral TRT

If a patient on Jatenzo 396 mg BID, confirmed to be taking the medication with adequate fat at each meal, cannot maintain average testosterone above 300 ng/dL after 4 to 6 weeks, switching to injectable testosterone cypionate (100 to 200 mg weekly or biweekly) is the most evidence-supported next step [5]. Persistence with an inadequate oral regimen exposes the patient to ongoing hypogonadal symptoms without benefit.

Practical Titration Protocol: Step-by-Step

A clear protocol reduces prescribing errors and ensures patients reach the right dose efficiently.

Step 1: Initiate at 237 mg BID

Prescribe 237 mg capsules. Instruct the patient to take one capsule with breakfast and one with dinner, each meal containing at least 15 g of dietary fat [1]. Schedule a follow-up lab draw for 14 to 28 days after initiation.

Step 2: Measure Total Testosterone at the Correct Window

Draw serum total testosterone 3 to 5 hours after the morning dose. If the result is between 300 and 1,050 ng/dL, maintain the current dose. If below 300, escalate to 396 mg BID. If above 1,050 ng/dL, reduce to 158 mg BID [1].

Step 3: Reassess After Dose Change

After any dose adjustment, repeat the same lab protocol in another 14 to 28 days. Check hematocrit and blood pressure at this visit. If the patient is now on 396 mg and still below target, evaluate compliance, meal fat content, concomitant medications (especially CYP3A4 inducers), and consider alternative formulations [4][5].

Step 4: Ongoing Monitoring

Once stable, monitor total testosterone, hematocrit, PSA, and blood pressure at 3 months, 6 months, and annually [5]. The Endocrine Society recommends a digital rectal exam at baseline and follow-up in men over 40, though PSA monitoring alone is increasingly accepted in clinical practice [5].

Jatenzo vs. Injectable Testosterone at Maximum Doses

Comparing Jatenzo's ceiling to injectable testosterone provides useful clinical context for patients who want to understand their options.

Efficacy Comparison

Injectable testosterone cypionate at 200 mg every 2 weeks produces mean peak testosterone levels of approximately 900 to 1,100 ng/dL and troughs of 300 to 400 ng/dL [6]. Jatenzo 396 mg BID produces a Cavg of approximately 489 ng/dL with less pronounced peaks and troughs [2]. For patients who prefer stable daily levels and oral convenience, the trade-off is a lower mean level than peak injectable values.

Side Effect Profile Differences

The polycythemia rate with injectable testosterone cypionate 200 mg biweekly ranges from 5 to 15% in observational studies [6]. Jatenzo's registration trial reported 0% polycythemia events at any dose tier [2]. The blood pressure warning is unique to Jatenzo among testosterone formulations. Patients with uncontrolled hypertension (systolic >140 mmHg) may be better candidates for transdermal or injectable formulations that lack this boxed warning.

Cost and Access

Jatenzo carries a higher out-of-pocket cost than generic injectable testosterone cypionate. A 30-day supply of Jatenzo at 396 mg BID typically ranges from $500 to $700 with commercial insurance, compared to $30 to $80 for a 10 mL vial of testosterone cypionate 200 mg/mL [4]. Prior authorization is commonly required for Jatenzo, particularly at the max dose.